Published : 11 September, 2024
In an industry article published in ET HealthWorld , Mr. D. S. Negi, CEO, Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), along with Dr. Vineet Talwar, Director, Department of Medical Oncology, RGCIRC shared their views on the central government’s recent announcement of reduction in GST rates from 12% to 5% on cancer drugs following 54th GST Council meeting. They emphasised on how GST reduction on lifesaving drugs will help in making cancer treatment affordable.
RGCIRC, Niti Bagh
